Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenxoneWAR:GX1 -0.35%66 Days Payable is 32.19 as of Mar. 2026, which is 9% below its 10-year median of 35.48. GuruFocus rates WAR:GX1 with a GF Score™ of 66/100 and a GF Value™ of zł6.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, Genxone ranks worse than 75.5% on this metric.
Genxone's average Accounts Payable for the
three
months ended in Mar. 2026 was zł0.08 Mil. Genxone's Cost of Goods Sold for the
three
months ended in Mar. 2026 was zł0.23 Mil.
Hence, Genxone's Days Payable for the
three
months ended in Mar. 2026 was 32.19.
The historical rank and industry rank for Genxone's Days Payable or its related term are showing as below:
WAR:GX1'
s Days Payable Range Over the Past 10 Years
Min: 26.35 Med: 35.48 Max: 7539.34
Current: 37.47
During the past 8 years, Genxone's highest Days Payable was 7539.34. The lowest was 26.35. And the median was 35.48.
WAR:GX1's Days Payable is ranked worse than 75.5% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs WAR:GX1: 37.47
Genxone's Days Payable
declined
from Mar. 2025 (58.36) to Mar. 2026 (32.19).
It may suggest that Genxoneaccelerated paying its suppliers.
Genxone Days Payable Related Terms
Genxone Days Payable Historical Data
* Premium members only.
The historical data trend for Genxone's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:GX1 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Genxone's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genxone Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genxone's Days Payable distribution charts can be found below:
* The bar in red indicates where Genxone's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Genxone's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genxone (WAR:GX1) has a Days Payable of 32.19 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genxone and its competitors. This is near median its historical median of 35.48. Over the past decade, Genxone's Days Payable has ranged from 26.35 to 7,539.34. According to the industry distribution chart, Genxone ranks #530 out of 702 companies in the Biotechnology industry, placing it in the top 75.5%.
Is Genxone's Days Payable too high?
Genxone's current Days Payable of 32.19 is near median its 10-year median of 35.48. Over the past 10 years, this metric has ranged from a low of 26.35 to a high of 7,539.34. The Biotechnology industry median Days Payable is 113.10. Genxone's value of 32.19 is 71.5% below this industry median. Based on the distribution chart, Genxone ranks #530 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genxone has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genxone's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genxone ranks #530 out of 702 companies for Days Payable. This places Genxone in the lower half of its industry. The industry median Days Payable is 113.10. Genxone's value of 32.19 is 71.5% below this benchmark. Historically, Genxone's own Days Payable has ranged from 26.35 to 7,539.34 over the past decade. While the company's 10-year median is 35.48 vs. the industry median of 113.10, Genxone has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genxone's current Days Payable of 32.19 is 71.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genxone and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genxone's current Days Payable is 32.19, which is near median its own 10-year median of 35.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genxone stock overvalued right now?
Based on GuruFocus' analysis, Genxone (WAR:GX1) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.51, compared to a current price of zł5.68 — trading 12.7% below its estimated fair value. The current Days Payable is 32.19, which is near median its 10-year median of 35.48 and 71.5% below the Biotechnology industry median of 113.10. Genxone's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Genxone (WAR:GX1), the current Days Payable is 32.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genxone (WAR:GX1) Overvalued in 2026?
Based on GuruFocus' analysis, Genxone stock appears to be undervalued.
The current stock price of zł5.68 is trading 12.7% below its estimated GF Value™ of zł6.51.
GuruFocus considers Genxone to be Modestly Undervalued.
Key valuation signals for WAR:GX1:
Days Payable: 32.19 (near median its 10-year median of 35.48)
GF Value™: zł6.51 vs. price of zł5.68 (12.7% below fair value)
Industry Position: 71.5% below the Biotechnology median (#530 of 702)
No single metric tells the full story. See the WAR:GX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
66GF Score
Get the complete analysis for WAR:GX1
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:GX1 has been successfully added to your 
